Ad
related to: recombinant factor viii brand names- Sign Up for Updates
Sign up today to stay connected
on the latest about VONVENDI®.
- Surgical Considerations
Treatment can be used before and
during surgical procedures.
- On-Demand Treatment Info
Treatment can be used as an on-
demand therapy option.
- Facts About VWD
Explore facts about von Willebrand
disease and its impact on patients.
- Sign Up for Updates
Search results
Results from the WOW.Com Content Network
A purified factor VIII concentrate is made from human blood plasma. [14] A recombinant version is also available. [13] People may develop antibodies to factor VIII such that this medication becomes less effective. [15] Factor VIII was first identified in the 1940s and became available as a medication in the 1960s.
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.
Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. [5] [6] [7] Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). [5]
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate used to treat hemophilia A. [5] [6] The most common side effects include headache, cough, nausea, and fever. [5] Damoctocog alfa pegol was approved for medical use in the United States in August 2018, [7] and in the European Union in ...
Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.
It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding. [6] The human coagulation factor VIII in moroctocog alfa is not extracted from human blood but is produced by a method known as 'recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to ...
Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. [7] [9] [13] It was approved in the United States, the European Union, and Japan in 2013. [14] [15] [11] [9]
Factor VIII was first characterized in 1984 by scientists at Genentech. [13] The gene for factor VIII is located on the X chromosome (Xq28). The gene for factor VIII presents an interesting primary structure, as another gene is embedded in one of its introns. [14]
Ad
related to: recombinant factor viii brand names